Aimee Corso, healthcare industry veteran most recently at Amazon, to lead growth
Mirvie, a company bringing a personalized, predictive, and preventive approach to pregnancy complications, today announced Aimee Corso joins the company as Senior Vice President of Growth. Recognized for advancing patient engagement and empowerment by creating a more patient-centric view of healthcare delivery, she will lead the launch of Mirvie’s first test using RNA to predict pregnancy complications months in advance.
“Adopting a new standard of predictive and preventive care is vital to improving the unacceptably poor maternal health outcomes in the United States,” said Maneesh Jain, CEO and co-founder of Mirvie. “We’re thrilled to welcome Aimee to the team. Her track record of launching and scaling novel, category-defining healthcare innovations speaks for itself. Aimee’s deep knowledge of patient-centric models and partnerships, honed with the industry’s best brands, including Amazon Health, will accelerate the adoption of Mirvie’s breakthrough solution to create healthier futures for moms and their families.”
Rates of preeclampsia, a disorder of high-blood pressure in pregnancy which is a leading cause of maternal and fetal morbidity and mortality, have doubled over the past 15 years. Severe maternal morbidity has also doubled over the past two decades due to pregnancy complications. A new March of Dimes report highlights the dismal state of preterm birth in the U.S. as rates are at an all-time high and the number has steadily risen over the past 10 years.
“I am grateful for the opportunity to bring forward such important and high-evidence science because the status quo isn’t working, and now we can finally understand the biology of pregnancy complications using the Mirvie RNA platform,” said Aimee Corso, senior vice president of growth at Mirvie. “I have been a proponent of expanding access to personalized and predictive medicine throughout my career but industry progress has been too slow. I can think of no better concern than pregnancy health to showcase how a simple blood test can reduce healthcare costs and spare the trauma of pre-term birth and complications for families who were hoping for a joyous start to their child’s life.”
Aimee started at the bench of scientific research, but her passion for translating science compelled her into a successful career launching and scaling innovations that improve patient journeys and outcomes. She has more than two decades of experience launching healthcare products and services for companies from start-ups to Fortune 5. Most recently, she was at Amazon, where she spent more than five years driving expansion of customers and partnerships within the company’s two fast-growing healthcare businesses - Amazon Pharmacy and Amazon Business for healthcare providers. She has been recognized and contributed to national discussions on equitable healthcare delivery for underserved populations, health data privacy, and health literacy standards.
Mirvie is bringing a personalized, predictive, and preventive approach to pregnancy health with the first simple blood test to predict the risk of complications like preeclampsia, months in advance. Backed by rigorous clinical research, the proprietary Mirvie RNA platform reveals vital, actionable information about the unique biology of a pregnancy. This breakthrough allows pregnant women and their care teams to put a preventive action plan in place before a complication becomes a life-threatening crisis. Serious complications impact one in five pregnancies in the U.S., and Mirvie is committed to creating a world where every pregnancy is as safe and healthy as possible. Mirvie is backed by top-tier investors including Blackrock, Decheng Capital, Foresite Capital, General Catalyst, GV, Khosla Ventures, and Mayfield.
Kate Enos
Director of Media Relations
kate@mirvie.com
